Atlee was born in Atlanta, Georgia and completed his bachelor's degree at Berry College working with Dr. Dominic Qualley and nucleic binding proteins in retroviruses. He finished his undergraduate degree with an ACS-certified degree in Biochemistry. His current work involves ribonucleotide reducatase, which catalyzes the production of deoxyribonucleotides in all cells. Ribonucleotide reductase is the target of anti-cancer therapeutics. This protein uses a tyrosyl radical-diferric cofactor as a radical initiator. The Barry group seeks to understand how the oxidizing power of the intermediary tyrosyl free radical is controlled using reaction-induced FT-IR spectroscopy to gain insight into the movements of the electron and proton and describe the protein conformational landscape associated with the transfer.